B of A upgrade anchors bullish shift in PHVS as three signals align

B of A Securities upgraded PHVS to Buy this morning, with analyst Tazeen Ahmad citing deucrictibant's Phase 3 data as reinforcing the drug's HAE prophylaxis potential. The $44 price target was maintained. The stock trades at $30.68, up 3.5% over the past week, against a median decline of 2.5% for its closest peers.

The upgrade arrives as options positioning and retail attention have shifted sharply in the same direction, a convergence across four distinct signal types within the past three days.

Phase 3 data does the heavy lifting

The bull case on deucrictibant centres on an 83% reduction in monthly attack rate versus placebo over 24 weeks, with 87% in Type 1 and Type 2 patients, from the CHAPTER-3 trial in 85 patients. The safety profile has been described as competitive with leading injectable therapies. Guggenheim raised its target to $44 from $40 on September 10. Morgan Stanley lifted its target to $62 from $46 the following day, and Leerink Partners moved to $65 from $50 on the same date. The mean consensus target now sits at $51.38, roughly 67% above the current price.

The bear case is real: Pharvaris carries no revenue, has net losses, and $363 million in cash as of Q2 2026, providing runway into 2028. Regulatory approval and commercial uptake in a crowded HAE market remain open questions.

Options positioning confirms the shift

The put-call ratio has collapsed from a tight band of 1.83 to 1.92 through most of September and early October to 0.91 as of October 22. That is 2.1 standard deviations below the 20-day mean of 1.69. The move began on October 19 and has held across three consecutive sessions. Traders have been closing downside protection at a pace that stands out against the stock's own recent history.

Retail attention remains elevated

Wikipedia page views and ORTEX stock page traffic combined registered 6.6 standard deviations above the 90-day average as of October 19, per ORTEX Alt Data. That reading was the trigger for the first convergence report on this name two days ago. The attention spike has not faded, and it now sits alongside the B of A upgrade rather than ahead of it.

Cost to borrow recovers from its lows

The cost to borrow rose to 0.82% on October 22, up 168% week-on-week from the multi-month low of 0.31% recorded on October 15. The move is worth tracking. Availability remains very loose at 1,889%, up 61% over the past week, so the borrow market is not under pressure. The cost rise looks like a modest recalibration after an unusually sharp drop, not a tightening signal.

Short interest stands at 3.3% of free float, with around 2.1 million shares short. That level is not the story here.

What to watch

Earnings are due November 12. The last four prints produced moves of minus 4.5%, minus 1.1%, plus 10.0%, and minus 3.7% on the day. The options shift toward calls, if sustained into that date, will be the clearest read on how positioning has settled after today's upgrade.

---

Data summary

• B of A upgrade to Buy, $44 target, October 23
• PCR: 0.91 vs 20-day mean of 1.69, down 2.1 standard deviations
• Retail attention: 6.6 standard deviations above 90-day average (as of October 19)
• Cost to borrow: 0.82%, up 168% week-on-week; availability 1,889%
• SI: 3.3% of free float, 2.1 million shares short
• Consensus price target: $51.38; stock at $30.68
• Next earnings: November 12